RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Roche Holding Stock

Roche Holding Revenue 2024

Roche Holding Revenue

61.44 B CHF

Ticker

ROG.SW

ISIN

CH0012032048

WKN

855167

In 2024, Roche Holding's sales reached 61.44 B CHF, a 4.63% difference from the 58.72 B CHF sales recorded in the previous year.

The Roche Holding Revenue history

YEARREVENUE (undefined CHF)GROSS MARGIN (%)
2029e79.1654,44
2028e72.859,19
2027e69.362,18
2026e67.8663,50
2025e6566,29
2024e61.4470,14
202358.7273,39
202263.2870,56
202162.869,19
202058.3272,74
201961.4771,73
201856.8571,07
201753.370,54
201650.5870,69
201548.1570,77
201447.4672,79
201346.7873,63
201245.573,78
201142.5372,58
201047.4772,00
200949.0570,20
200845.6270,05
200746.1370,21
200642.0468,40
200535.5173,90
200429.5273,86

Roche Holding Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Roche Holding, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Roche Holding from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Roche Holding’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Roche Holding. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Roche Holding’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Roche Holding’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Roche Holding’s growth potential.

Roche Holding Revenue, EBIT and net profit per share

DateRoche Holding RevenueRoche Holding EBITRoche Holding Net Income
2029e79.16 B CHF0 CHF17.51 B CHF
2028e72.8 B CHF25.51 B CHF16.07 B CHF
2027e69.3 B CHF24.17 B CHF15.31 B CHF
2026e67.86 B CHF22.87 B CHF14.75 B CHF
2025e65 B CHF21.52 B CHF13.75 B CHF
2024e61.44 B CHF19.82 B CHF12.54 B CHF
202358.72 B CHF18.53 B CHF11.5 B CHF
202263.28 B CHF19.92 B CHF12.42 B CHF
202162.8 B CHF18.53 B CHF13.93 B CHF
202058.32 B CHF18.97 B CHF14.3 B CHF
201961.47 B CHF20.23 B CHF13.5 B CHF
201856.85 B CHF18.71 B CHF10.5 B CHF
201753.3 B CHF16.92 B CHF8.63 B CHF
201650.58 B CHF16.93 B CHF9.58 B CHF
201548.15 B CHF16.06 B CHF8.86 B CHF
201447.46 B CHF16.98 B CHF9.33 B CHF
201346.78 B CHF17.39 B CHF11.16 B CHF
201245.5 B CHF16.66 B CHF9.43 B CHF
201142.53 B CHF14.61 B CHF9.34 B CHF
201047.47 B CHF13.49 B CHF8.67 B CHF
200949.05 B CHF12.28 B CHF7.78 B CHF
200845.62 B CHF13.9 B CHF8.97 B CHF
200746.13 B CHF14.47 B CHF9.76 B CHF
200642.04 B CHF11.73 B CHF7.88 B CHF
200535.51 B CHF8.78 B CHF5.92 B CHF
200429.52 B CHF6.19 B CHF6.61 B CHF

Roche Holding stock margins

The Roche Holding margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Roche Holding. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Roche Holding.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Roche Holding's sales revenue. A higher gross margin percentage indicates that the Roche Holding retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Roche Holding's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Roche Holding's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Roche Holding's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Roche Holding. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Roche Holding's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Roche Holding Margin History

Roche Holding Gross marginRoche Holding Profit marginRoche Holding EBIT marginRoche Holding Profit margin
2029e73.39 %0 %22.12 %
2028e73.39 %35.04 %22.07 %
2027e73.39 %34.87 %22.09 %
2026e73.39 %33.7 %21.73 %
2025e73.39 %33.1 %21.15 %
2024e73.39 %32.26 %20.42 %
202373.39 %31.56 %19.58 %
202270.56 %31.47 %19.63 %
202169.19 %29.51 %22.18 %
202072.74 %32.52 %24.51 %
201971.73 %32.9 %21.96 %
201871.07 %32.92 %18.47 %
201770.54 %31.74 %16.2 %
201670.69 %33.47 %18.93 %
201570.77 %33.36 %18.41 %
201472.79 %35.78 %19.66 %
201373.63 %37.17 %23.86 %
201273.78 %36.62 %20.72 %
201172.58 %34.36 %21.97 %
201072 %28.41 %18.25 %
200970.2 %25.03 %15.87 %
200870.05 %30.46 %19.66 %
200770.21 %31.36 %21.16 %
200668.4 %27.9 %18.74 %
200573.9 %24.72 %16.68 %
200473.86 %20.98 %22.38 %

Roche Holding Aktienanalyse

What does Roche Holding do?

Roche Holding AG is a Swiss company that operates in the pharmaceutical and diagnostics sectors. It was founded in Basel in 1896 by Fritz Hoffmann-La Roche and is now one of the largest pharmaceutical companies in the world. The business model of Roche is based on research, development, and distribution of innovative medications and diagnostics for the early detection, diagnosis, and treatment of diseases. Its customers include doctors, hospitals, and laboratories. Roche has three operating divisions: Pharma, Diagnostics, and Genentech. The Pharma division is responsible for the development and marketing of prescription drugs, the Diagnostics division offers a wide range of products for disease diagnosis, and the Genentech division focuses on the development of biotechnological drugs. Roche is known for its strong research investments in new medications and has played a significant role in the history of drug development. The company employs approximately 94,000 people worldwide and is listed on the Swiss stock exchange (SIX: ROG). Some of its well-known products include the cancer drug Avastin, the multiple sclerosis drug Ocrevus, and the diabetes medication RoActemra. Roche is also known for its innovative diagnostic products and has developed numerous tests for disease detection. In recent years, the company has expanded its activities into new therapy areas such as immunotherapy and gene therapy, and it has a strong pipeline of new medications and diagnostics that will be launched in the coming years. Overall, Roche has played a significant role in drug development and diagnostics since its inception, and with its research investments and diverse product portfolio, it will continue to play an important role in the healthcare industry. Roche Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Roche Holding's Sales Figures

The sales figures of Roche Holding originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Roche Holding’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Roche Holding's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Roche Holding’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Roche Holding stock

How much revenue did Roche Holding generate this year?

Roche Holding has achieved a revenue of 61.44 B CHF this year.

How much was the turnover of the company Roche Holding compared to the previous year?

The revenue of Roche Holding has increased by 4.63% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Roche Holding?

The revenue of Roche Holding is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Roche Holding measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Roche Holding so important for investors?

The revenue of Roche Holding is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Roche Holding pay?

Over the past 12 months, Roche Holding paid a dividend of 9.5 CHF . This corresponds to a dividend yield of about 3.42 %. For the coming 12 months, Roche Holding is expected to pay a dividend of 11.25 CHF.

What is the dividend yield of Roche Holding?

The current dividend yield of Roche Holding is 3.42 %.

When does Roche Holding pay dividends?

Roche Holding pays a quarterly dividend. This is distributed in the months of April, April, April, April.

How secure is the dividend of Roche Holding?

Roche Holding paid dividends every year for the past 37 years.

What is the dividend of Roche Holding?

For the upcoming 12 months, dividends amounting to 11.25 CHF are expected. This corresponds to a dividend yield of 4.05 %.

In which sector is Roche Holding located?

Roche Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Roche Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Roche Holding from 3/18/2024 amounting to 9.6 CHF, you needed to have the stock in your portfolio before the ex-date on 3/14/2024.

When did Roche Holding pay the last dividend?

The last dividend was paid out on 3/18/2024.

What was the dividend of Roche Holding in the year 2023?

In the year 2023, Roche Holding distributed 9.3 CHF as dividends.

In which currency does Roche Holding pay out the dividend?

The dividends of Roche Holding are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Roche Holding

Our stock analysis for Roche Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Roche Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.